Skip to main content
Virax Biolabs Group Limited (VRAX)
NASDAQ: VRAX · Real-Time Price · USD
0.6095
-0.0346 (-5.37%)
Nov 11, 2026, 11:12 AM EST - Market open

Virax Biolabs Group Financials Overview

Millions USD. Fiscal year is Apr - Mar.

Revenue & Profits
Chart
Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Revenue
0.010.010.010.160.01-
Revenue Growth
316.04%96.23%-95.95%1727.11%--
Gross Profit
0.010.01-0.050.05-0-
Operating Income
-6.4-6.4-6.08-6.14-5.73-1.73
Net Income
-5.02-5.02-6.06-6.73-5.46-1.71
Earnings Per Share
-12.64-12.64-40.62-83.90-128.35-44.75
EPS Growth
------

Cash & Debt
Chart
Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Cash & Investments
6.526.524.323.679.40.03
Total Debt
0.410.410.380.220.16-
Net Cash (Debt)
6.16.13.953.449.240.03
Net Cash Growth
110.49%54.68%14.64%-62.73%33181.39%-
Net Cash Per Share
15.3515.3526.4542.89217.250.73

Cash Flow & CapEx
Chart
Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Operating Cash Flow
-4.62-4.62-4.56-6.4-4.18-0.81
Capital Expenditures
-0.26-0.26-0.6-0.95--
Free Cash Flow
-4.88-4.88-5.17-7.35-4.18-0.81
Free Cash Flow Growth
------

Margins
Chart
Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Gross Margin
61.90%61.90%-32.34%-15.94%-
Operating Margin
-51515.17%-51515.17%-95984.87%-3922.37%-66963.68%-
Pretax Margin
-47753.55%-47753.55%-97992.31%-4308.38%-63751.47%-
Profit Margin
-40439.11%-40439.11%-95739.17%-4304.81%-63748.32%-
FCF Margin
-39263.65%-39263.65%-81621.64%-4698.55%-48823.35%-

Valuation
Chart
Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingNov '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
PS Ratio
41.32131.40781.8410.831262.87-